AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. AVE has ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast ...

Researchers from University of Arizona present a new therapeutic target to shield nerve cells from the damage of ALS.

New research offers fresh hope to patients with colorectal cancer, as advances in liquid biomarker technologies are ...

(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

Researchers have identified a previously overlooked mechanism of brain cell death that appears to play a major role in ...

End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure ...

Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...

Scientists have developed Spudcell, an advanced synthetic cell capable of adapting to its environment and learning survival skills, marking a breakthrough in synthetic biology.

Permeasis Therapeutics (“Permeasis”), a biotechnology company developing intracellular biologics enabled by its proprietary Membrane Translocation Domain (MTD) platform announced the publication of ...